参考文献/References:
[1] Manzi S,Meilahn EN,Rairie JE,et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study[J]. Am J Epidemiol,1997,145(5):408-415.
[2] Hosenpud JD,Montanaro A,Hart MV,et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus[J]. Am J Med, 1984,77(2):286- 292.
[3] Rivera-López R,Jiménez-Jáimez J,Sabio JM,et al. Relationship between QT interval length and arterial stiffness in systemic lupus erythematosus(SLE):a cross-sectional case-control study[J]. PLoS One,2016,11(4):e0152291.
[4] Manzi S,Selzer F,Sutton-Tyrrell K,et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus[J]. Arthritis Rheum ,1999,42(1):51-60.
[5] Frerix M,Stegbauer J,Kreuter A,et al.Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus:a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events[J]. Arthritis Res Ther,2014,16(1):R54.
[6] Zardi EM,Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus:are they early markers of subclinical atherosclerosis?[J]. Autoimmun Rev,2010,9(10):684-686.
[7] Hirata K,Kadirvelu A,Kinjo M,et al. Altered coronary vasomotor function in young patients with systemic lupus erythematosus[J]. Arthritis Rheum,2007,56(6):1904-1909.
[8] Bruce IN,Burns RJ,Gladman DD,et al. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. prevalence and distribution of abnormalities[J]. J Rheumatol,2000,27(10):2372-2377.
[9] Nikpour M,Gladman DD,Iba?ez D,et al. Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus[J]. J Rheumatol,2009,36(2):288-294.
[10] Doukky R,Hayes K,Frogge N,et al. Impact of appropriate use on the prognostic value of single-photon emission computed tomography myocardial perfusion imaging[J]. Circulation,2013,128(15):1634-1643.
[11] Tselios K,Sheane BJ,Gladman DD,et al. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus:a systematic review[J]. J Rheumatol,2016,43(1):54-65.
[12] Varma N,Hinojar R,D’Cruz D,et al. Coronary vessel wall contrast enhancement imaging as a potential direct marker of coronary involvement:integration of findings from CAD and SLE patients[J]. JACC Cardiovasc Imaging,2014,7(8):762-770.
[13] Morreale M,Mulè G,Ferrante A,et al. Early vascular aging in normotensive patients with systemic lupus erythematosus:comparison with young patients having hypertension[J]. Angiology,2016,67(7):676-682.
[14] Bruce IN,Gladman DD,Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus[J]. Rheum Dis Clin North Am,2000,26(2):257-278.
[15] Karrar A,Sequeira W,Block JA. Coronary artery disease in systemic lupus erythematosus:a review of the literature[J]. Semin Arthritis Rheum,2001,30(6):436-443.
[16] Urowitz MB,Iba?ez D,Su J,et al. Modified Framingham Risk Factor Score for systemic lupus erythematosus[J]. J Rheumatol,2016,43(5):875-879.
[17] Chung CP,Oeser A,Avalos I,et al. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus[J]. Lupus,2006,15(9):562-569.
[18] 汪汉,蔡琳. 类风湿关节炎血脂特征及其管理[J].心血管病学进展,2013,34(4):503-508.
[19] Tselios K,Koumaras C,Gladman DD,et al. Dyslipidemia in systemic lupus erythematosus:just another comorbidity?[J].Semin Arthritis Rheum,2016,45(5):604-610.
[20] Skaggs BJ,Hahn BH,McMahon M. Accelerated atherosclerosis in patients with SLE—mechanisms and management[J]. Nat Rev Rheumatol,2012,8(4):214-223.
[21] Juárez-Rojas JG,Medina-Urrutia AX,Jorge-Galarza E,et al. Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus:a double-blind randomized clinical trial[J]. Lupus,2012,21(1):27-35.
[22] Huo Y,Li J,Qin X,et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China:the CSPPT randomized clinical trial[J]. JAMA,2015,313(13):1325-1335.
[23] 张翠,蔡琳,汪汉. 结缔组织病与心力衰竭[J].心血管病学进展,2018,39(4):677-681.
[24] Sazliyana S,Mohd Shahrir MS,Kong CT,et al. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients[J]. Lupus,2011,20(12):1260-1266.
[25] Ridker PM,Hennekens CH,Buring JE,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med,2000,342(12):836-843.
[26] Hulley S,Grady D,Bush T,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study(HERS) Research Group[J]. JAMA,1998,280(7):605-613.
[27] Yang DH,Leong PY,Sia SK,et al. Long-term hydroxychloroquine therapy and risk of coronary artery disease in patients with systemic lupus erythematosus[J]. J Clin Med,2019,8(6).pii:E796.
[28] Schreiber K,Breen K,Parmar K,et al. The effect of hydroxychloroquine on haemostasis,complement, inflammation and angiogenesis in patients with antiphospholipid antibodies[J]. Rheumatology(Oxford),2018,57(1):120-124.
[29] Bessant R,Duncan R,Ambler G,et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus:a case-control study[J]. Arthritis Rheum,2006,55(6):892-899.
[30] Ura M,Sakata R,Nakayama Y,et al. Coronary artery bypass grafting in patients with systemic lupus erythematosus[J]. Eur J Cardiothorac Surg,1999,15(5):697-701.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(5):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(5):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]